CURRENT PARTICIPANTS IN THE COMPANION DIAGNOSTICS INDUSTRY In Vitro Diagnostics, Biomarker and Companion Diagnostics Companies...
|
|
- Bryan West
- 5 years ago
- Views:
Transcription
1 CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 SCOPE OF REPORT... 1 METHODOLOGY AND INFORMATION SOURCES... 2 INTENDED AUDIENCE... 2 ANALYST CREDENTIALS... 2 RELATED REPORTS... 3 BCC ONLINE SERVICES... 3 DISCLAIMER... 3 CHAPTER TWO: SUMMARY... 4 SUMMARY... 4 SUMMARY TABLE U.S. NET SALES OF ONCOTYPE AND TROFILE THROUGH 2015 ($ MILLIONS)... 5 SUMMARY FIGURE U.S. NET SALES OF ONCOTYPE AND TROFILE ($ MILLIONS)... 6 CHAPTER THREE: OVERVIEW, STRUCTURE AND SIGNIFICANCE OF THE COMPANION DIAGNOSTICS INDUSTRY... 7 COMPANION DIAGNOSTICS AS A NEW TREND IN PERSONALIZED MEDICINE... 7 HISTORICAL OVERVIEW... 7 TABLE 1 PERCENTAGE OF PRODUCTS IN EACH SECTOR OF THE COMPANION DIAGNOSTICS INDUSTRY (%)... 8 FIGURE 1 PERCENTAGE OF PRODUCTS IN EACH SECTOR OF THE COMPANION DIAGNOSTICS INDUSTRY... 8 PERSONALIZED MEDICINE TREND OVERVIEW... 8 TABLE 2 OVERVIEW OF PERSONALIZED MEDICINE PRODUCTS... 9 TABLE 3 PERCENTAGE OF EACH PERSONALIZED MEDICINE PRODUCT CATEGORY IN 2008 AND THEIR FORECAST, 2008 AND 2012 (%) FIGURE 2 PERCENTAGE OF EACH PERSONALIZED MEDICINE PRODUCT CATEGORY IN 2008 AND THEIR FORECAST, 2008 AND 2012 (%) FIGURE 2 (CONTINUED) TABLE 4 ESTIMATE FOR COMPANION DIAGNOSTICS TEST MARKET FOR THERAPY SELECTION, THROUGH 2015 ($ MILLIONS)... 12
2 CURRENT PARTICIPANTS IN THE COMPANION DIAGNOSTICS INDUSTRY In Vitro Diagnostics, Biomarker and Companion Diagnostics Companies In Vitro Diagnostics Companies Biomarker Research Companies Companion Diagnostics Companies Laboratory Test Services Companies (CLIA Laboratories) Pharmaceutical Companies Regulatory Entities, Insurance Companies and Healthcare Providers Regulatory Entities Insurance Companies Healthcare Providers Patients, Physicians and Public Opinion as Additional Drivers of the Companion Diagnostic Industry Patients, Physicians and (Continued) Organizations Supporting the Personalized Medicine Approach FIGURE 3 DRIVERS OF COMPANION DIAGNOSTICS INDUSTRY CHALLENGES AND OBSTACLES TO COMPANION DIAGNOSTICS INDUSTRY DEVELOPMENT Challenges and obstacles of (Continued) FIGURE 4 CHALLENGES OF COMPANION DIAGNOSTICS INDUSTRY BIOMARKERS MARKET AS BASIS FOR THE COMPANION DIAGNOSTICS INDUSTRY TABLE 5 GLOBAL BIOMARKER MARKET ($ BILLIONS) TABLE 6 WORLDWIDE MARKET FOR BIOMARKERS ACCORDING TO RESEARCH AREAS IN 2008 ($ BILLIONS) CANCER BIOMARKERS CARDIOVASCULAR DISEASE BIOMARKERS CNS DISORDERS BIOMARKERS IN VITRO DIAGNOSTICS (IVD) INDUSTRY AS A DRIVER FOR THE COMPANION DIAGNOSTICS FIELD TABLE 7 ESTIMATE FOR MAJOR PLAYERS OF IVD COMPANIES IN 2010 (%) EFFECT OF THE REGULATORY ASPECT ON COMPANION DIAGNOSTICS INDUSTRY DEVELOPMENT TABLE 8 COMPANION DIAGNOSTICS, ASSOCIATED DRUGS AND REGULATORY APPROVAL STATE... 26
3 COMPANION DIAGNSOTICS COST AND REIMBURSMENT POLICIES AS DRIVERS FOR INDUSTRY DEVELOPMENT TABLE 9 COMPANION DIAGNOSTICS COST EXAMPLES (DOLLARS) TABLE 10 EXAMPLES OF COMPANION DIAGNOSTICS EFFECT ON HEALTHCARE SAVINGS ($ MILLIONS) GENERAL IMPACT OF PERSONALIZED MEDICINE TREND ON MARKET DEVELOPMENT IN OTHER INDUSTRIES TABLE 11 MARKET SEGMENT ESTIMATES IN PERSONALIZED MEDICINE 2010 AND 2015 ($ BILLIONS) GENERAL IMPACT OF PERSONALIZED (CONTINUED) GENERAL IMPACT OF PERSONALIZED (CONTINUED) ADDITIONAL PERSONOLIZED MEDICINE PRODUCTS ON THE MARKET TABLE 12 ADDITIONAL PERSONALIZED MEDICINE PRODUCTS ON THE MARKET FOR THE GENERAL PUBLIC ($) Direct to Consumer Genetic Tests or At Home Genetic Tests Direct to Consumer (Continued) Personal Genome Sequencing PATENT APPLICATIONS FOR COMPANION DIAGNOSTICS AND BIOMARKERS TABLE 13 PATENT APPLICATIONS WORLDWIDE IN DIFFERENT BIOMARKER RESEARCH FIELDS, FIGURE 5 PATENT APPLICATION WORLDWIDE IN DIFFERENT BIOMARKER RESEARCH FIELDS, EXAMPLES OF RECENT PATENT APPLICATIONS AND GRANTED PATENTS IN THE COMPANION DIAGNOSTICS INDUSTRY Power3/StemTroniX Aveo Pharmaceuticals Clarient Inc Entelos CURRENT TECHNIQUES AND TECHNOLOGIES FOR COMPANION DIAGNOSTICS TABLE 14 ADVANTAGES AND DISADVANTAGES OF MOST COMMON TECHNIQUES FOR COMPANION DIAGNOSTICS DIGITAL PATHOLOGY AND QUANTITATIVE IMMUNOSTAINING AS A NEW TREND IN COMPANION DIAGNOSTIC ASSAY DEVELOPMENT NEW SCIENTIFIC APPROACHES TO COMPANION TEST DEVELOPMENT... 42
4 MicroRNA (mirna) Profiling Imaging as a New Approach to Companion Diagnostics Tests Cognitive Diagnostics as Companion Diagnostics Test GENETIC KNOWLEDGE AND CLINICIAN OPINION AS DRIVERS FOR COMPANION DIAGNOSTICS MARKET TABLE 15 STATISTICS IN THE U.S. FOR PHYSICIAN OPINION REGARDING COMPANION DIAGNOSTIC TESTS AS PART OF DIAGNOSIS AND PATIENT TREATMENT (%) TABLE 16 CURRENT STATISTICS ON PHYSICIAN OPINION IN DIFFERENT ASPECTS OF PERSONALIZED MEDICINE IN THE U.S. (%) TABLE 16 (CONTINUED) LIST OF COMPANION DIAGNOSTICS COMPANIES AND EVALUATION OF MARKET PARTICIPANTS TABLE 17 CURRENT MARKET PARTICIPANTS IN COMPANION DIAGNOSTICS TABLE 17 (CONTINUED) TABLE 17 (CONTINUED) TABLE 17 (CONTINUED) TABLE 17 (CONTINUED) CURRENT MARKET ANALYSIS Roche Diagnostics Qiagen DAKO, Quest Diagnostics and LabCorp Other Competitors in the Market Newcomers to Companion Diagnostics Field Life Technologies GenProbe GE Healthcare Acquisitions and Partnerships Trend Major Pharmaceutical Companies as Partners for Companion Diagnostics Companies TABLE 18 EXAMPLES OF PARTNERSHIPS BETWEEN PHARMA AND DIAGNOSTIC COMPANIES AND TESTS DEVELOPED BETWEEN 2007 AND TABLE 19 NUMBER AND PERCENTAGE OF DEALS IN COMPANION DIAGNOSTICS ACCORDING TO RESEARCH AREAS Failures and Lessons from Companion Diagnostics Development Nanosphere Inc
5 Perlegen Sequenom Companion Tests as a Strategy to Improve Drug Sales Performance Companion Diagnostics as a Strategy for Failing Drugs CHAPTER FOUR: COMPANION DIAGNOSTICS INDUSTRY OVERVIEW IN DIFFERENT RESEARCH AREAS CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS IN CANCER OVERVIEW TABLE 20 COMMON COMPANION DIAGNOSTIC TESTS IN CANCER APPLICATIONS TABLE 20 (CONTINUED) MAIN COMPANION DIAGNOSTICS ASSAY IN ONCOLOGY DRUG MARKET Her2 Test Manufacturers of Her2/neu Assay Manufacturers (Continued) Manufacturers (Continued) Kirsten Ras Sarcoma (KRAS) Test KRAS Test Market Participants TABLE 21 PRICE COMPARISON FOR DIFFERENT KRAS TEST MANUFACTURERS (DOLLARS) EGFR Expression Test Manufacturers of EGFR Kits UGT1A1 test Genetic Assays for Breast Cancer Prognosis BRCA1/ Aviara Breast Cancer Index/Cancer Type ID/ Aviara MGI MammaPrint Oncotype Dx Mammostrat Market Analysis for Cancer Prognosis Testing TABLE 22 SALES OF ONCOTYPE DX WORLDWIDE, THROUGH 2015 ($ MILLIONS) FIGURE 6 SALES OF ONCOTYPE DX WORLDWIDE, THROUGH 2015 ($ MILLIONS) Additional Molecular Markers and Products as Companion Diagnostics for Drug Response... 71
6 Target GI Analysis for Erbitux/Vectibix/Fluorouracil/Camptosar Treatments BCR ABL Analysis for Gleevec Treatment Thiopurine S methyltransferase (TPMT) Activity for Purinethol/Thioguanine/ Azathioprine Treatments Deficiency of Dihydropyrimidine Dehydrogenase (DPD) Activity for 5 Fluorouracil CupPrint for Chemotherapy Treatments G6PD Deficiency for Elitek Treatment PGx Predict for Rituximab Treatment c Kit for Gleevec Treatment in Stomach Cancer CD33 Marker for Mylotarg Treatment CD25 Marker for Ontak Therapy SUMMARY OF COMPANION DIAGNOSTICS ONCOLOGY MARKET TABLE 23 MARKET SHARE FOR COMPANION DIAGNOSTICS KIT DEVELOPERS IN THE ONCOLOGY MARKET, 2010 (%) FIGURE 7 MARKET SHARE FOR COMPANION DIAGNOSTICS KIT DEVELOPERS IN ONCOLOGY MARKET, 2010 (%) INFLUENCE OF CANCER STATISTICS, HEALTHCARE COSTS AND DRUG MARKET ON COMPANION DIAGNOSTICS DEVELOPMENT CANCER STATISTICS OVERVIEW TABLE 24 TOTAL U.S. CANCER STATISTICS AS ESTIMATED BY ACS AND NCI, Breast Cancer Lung Cancer Colorectal Cancer Leukemia HEALTHCARE COSTS AS A FACTOR FOR COMPANION DIAGNOSTICS DEVELOPMENT TABLE 25 AVERAGE ANNUAL HEALTHCARE COST FOR DIFFERENT TYPES OF CANCER IN THE U.S. AND AMOUNT SPENT ON SCIENTIFIC RESEARCH IN KRAS Companion Diagnostics as an Example for New Health Economics Model TABLE 26 ESTIMATE FOR COST SAVINGS USING COMPANION DIAGNOSTIC TEST FOR KRAS IN COLORECTAL CANCER PATIENTS... 78
7 EFFECT OF DRUG MARKET ON COMPANION DIAGNOSTICS PRODUCT DEVELOPMENT TABLE 27 EXAMPLES OF DRUGS SALES WORLDWIDE ASSOCIATED WITH COMPANION DIAGNOSTICS TESTS ON THE MARKET ($ BILLIONS) Herceptin and Her2 Test Vectibix and KRAS test PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND THE PHARMACEUTICAL INDUSTRY IN THE ONCOLOGY SECTOR OVERVIEW TABLE 28 EXAMPLES OF PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND THE PHARMACEUTICAL INDUSTRY IN ONCOLOGY, Qiagen/DxS and Partnerships DxS/ Amgen DxS/ Bristol Myers Squibb/ImClone Systems DxS/ Exosome Diagnostics DxS/ Genzyme Corporation DxS/AstraZeneca DxS/Boehringer Amgen/Lab Almac Diagnostics Partnerships Almac Diagnostics/Eli Lilly Almac Diagnostics/Merck KGaA and U.K. Medical Research Council Abbott Diagnostics/ Pfizer Ipsogen/ ARUP Epigenomics/Bristol Meyer Squibb (BMS) and J&J Celera/Merck and Abbott Laboratories DAKO Partnerships DAKO/Genentech (Roche) DAKO/OSI Pharmaceuticals and BMS DAKO/ Genentech, OSI Pharmaceuticals and Roche Roche/ Plexxikon BioMerieux/Ipsen NEW DEALS AND PARTNERSHIPS BETWEEN PHARMACEUTICAL COMPANIES AND COMPANION DIAGNOSTICS IN ONCOLOGY (DURING 2010) OVERVIEW... 87
8 TABLE 29 RECENT PARTNERSHIPS AND COLLABORATIONS BETWEEN PHARMA, ACADEMICS AND COMPANION DIAGNOSTICS COMPANIES DURING Almac Diagnostics/Aeterna Zentaris Althea DX/The Nicholas Conor Institute for Pediatric Cancer Research BioMerieux/GSK Companion Diagnostics Inc./University of Indianapolis DAKO/AstraZeneca DxS (Qiagen)/Pfizer DxS (Qiagen)/ Johns Hopkins University (JHU) Response Genetics/GSK TCLand Expression/Inserm Ventana Medical Systems/Clavis Pharma ASA ANALYSIS OF PARTNERSHIPS TREND CURRENT COMPANION DIAGNOSTICS TESTS ON THE MARKET FOR METABOLIC DISORDERS OVERVIEW TABLE 30 COMPANION DIAGNOSTICS TESTS ON THE MARKET FOR METABOLIC DISEASES Fibromax Entelos Lipomics Technologies/Tethys Bioscience Biocrates Companion Diagnostics Development Genomas PhyzioType System LDLR/Atorvastatin PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND PHARMACEUTICALS/ACADEMICS IN DEVELOPMENT OF COMPANION ASSAYS FOR METABOLIC DISORDERS OVERVIEW TABLE 31 PARTNERSHIPS AND COLLABORATION BETWEEN COMPANION DIAGNOSTICS COMPANIES AND PHARMACEUTICALS/ACADEMICS, Lipomics Technologies (Tethys Bioscience)/Joslin Diabetes Center (Harvard Medical School) Genomas/ University of Puerto Rico Medical Science Campus decode Genetics/Celera Corp Siemens/LabCorp Celgene Corp./ Agios Pharmaceuticals Inc
9 Biocrates/Pfizer, Altana Pharma MARKET POTENTIAL FOR COMPANION DIAGNOSTICS TESTS IN METABOLIC DISORDERS TABLE 32 STATISTICS AND MARKET SIZE FOR DIABETES, HYPERCHOLESTEROLEMIA AND METABOLIC SYNDROME IN THE U.S., Market Potential for Companion (Continued) CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS IN CARDIOVASCULAR DISEASES OVERVIEW TABLE 33 ANNUAL STATISTICS FOR CARDIOVASCULAR DISEASE IN THE U.S. AND RELATED HEALTHCARE COSTS TABLE 34 CURRENT EXAMPLES OF COMPANION DIAGNOSTICS ON THE MARKET FOR CARDIOVASCULAR DISEASES Companion Diagnostics Test for Coumadin (Warfarin) TABLE 35 ANNUAL STATISTICS FOR COUMADIN TREATMENT IN THE U.S., Manufacturers of Companion Diagnostics Test for Warfarin (Coumadin) Nanosphere Inc AutoGenomics Osmotech/Genmark Diagnostics ParagonDx Entrogen Kimball Genetics Additional Companies Market Analysis for Warfarin Test Competitors Market Analysis for (Continued) TABLE 36 COMPARISON OF FOUR TESTS FOR WARFARIN SENSITIVTY BY FOUR DIFFERENT MANUFACTURERS Companion Diagnostics for Plavix Protein C Deficiency Test for Warfarin Sensitivity Drug Market Associated with Cardiovascular Companion Diagnostics Coumadin Plavix TABLE 37 NET SALES FOR PLAVIX ($ MILLIONS) PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND PHARMACEUTICALS IN CARDIOVASCULAR DISEASES
10 TABLE 38 CURRENT PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND PHARMACEUTICALS OR ACADEMICS IN THE CARDIOVASCULAR DISEASES SECTOR LABCORP/ARCA BIOPHARMA (NUVELO SUBSIDIARY) TABLE 39 U.S. STATISTICS FOR HEART FAILURE AND ANNUAL HEALTHCARE COST AFFOMIX CORP./UNIVERSITY OF MONTREAL PHARMACOGENOMICS CENTRE AND MONTREAL HEART INSTITUTE CELERA CORP./DECODE GENETICS CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS IN CNS DISORDERS TABLE 40 CURRENT COMPANION DIAGNOSTICS TESTS ON THE MARKET FOR CNS DISORDERS DRUG THERAPY HLA B*1502 ALLELE TESTING PHYZIOTYPE PIMS CURRENT COMPANION DIAGNOSTICS COMPANIES DEVELOPING COMPANION ASSAYS IN CNS DISORDERS TABLE 41 CURRENT COMPANION DIAGNOSTICS COMPANIES DEVELOPING COMPANION ASSAYS IN CNS DISORDERS SALADAX BIOMEDICAL CYTOX CURIDIUM MEDICA (AVACTA COMPANY) EXONHIT POPULATION DIAGNOSTICS POWER3 MEDICAL PRODUCTS PROTAGEN CURRENT PARTNERSHIPS BETWEEN DIAGNOSTIC COMPANIES AND THEIR PAHRMACEUTICAL PARTNERS DEVELOPING COMPANION TESTS IN CNS DISORDERS TABLE 42 RECENT PARTNERSHIPS IN THE FIELD OF COMPANION DIAGNOSTICS FOR CNS DISORDERS BETWEEN DIAGNOSTICS AND PHARMACEUTICAL COMPANIES PSYNOVA NEUROTECH (RBM)/ROCHE CURIDIUM MEDICA/TAKEDA SALADAX BIOMEDICAL/BRISTOL MYERS SQUIBB POWER3 MEDICAL PRODUCTS/STEMTRONIX PROTAGEN/ GERMAN FEDERAL MINISTRY OF RESEARCH AND EDUCATION S BIOPHARMA COMPETITION EXONHIT/ALLERGEN
11 STATISTICS, HEALTHCARE COST AND DRUG MARKET FOR CNS DISRODERS AS AN ESTIMATE FOR COMPANION DIAGNOSTICS ASSAY DEVELOPMENT TABLE 43 STATISTICS AND HEALTHCARE COST OF SCHIZOPHRENIA, ALZHEIMER S AND PARKINSON S IN THE U.S ($ BILLIONS) TABLE 44 CURRENT MARKET SIZE FOR NEURODEGENERATION DISORDERS AND SCHIZOPHRENIA IN THE U.S. ($ BILLIONS) SCHIZOPHRENIA AS A MARKET FOR COMPANION DIAGNOSTICS DEVELOPMENT NEURODEGENERATIVE DISORDERS AS A MARKET FOR COMPANION DIAGNOSTICS DEVELOPMENT Parkinson s and Current Drug Treatment TABLE 45 NET SALES OF MIRAPEX AND REQUIP ($ MILLIONS) Alzheimer s and Current Drug Treatment TABLE 46 NET SALES OF NAMENDA AND ARICEPT ($ MILLIONS) BIOMARKER RESEARCH FOR NEURODEGENERATION AS A DRIVER FOR COMPANION DIAGNOSTICS Alzheimer s Biomarker Trend Alzheimer s Biomarker Trend (Continued) Main CSF Biomarkers in Alzheimer s Aβ Total tau protein Hyperphosphorylated tau (P tau) Isoprostanes Cytokines Other Biomarkers Parkinson s Biomarker Trend Future Trends for Development of Companion Diagnostics for CNS Disorders CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS TESTS IN INFECTIOUS DISEASES TABLE 47 CURRENT COMPANION DIAGNOSTICS TESTS ON THE MARKET FOR INFECTIOUS DISEASES GENETIC TEST FOR HLA B TROPISM FOR HIV ASSAY TABLE 48 REVENUES FROM TROFILE SALES BY MONOGRAM/LABCORP ($ MILLIONS) Competitors of Trofile Assay
12 Other New Opportunities for Trofile Use TABLE 49 ENTRY INHIBITORS DRUG DISCOVERY AS NEW OPPORTUNITY FOR TROFILE ASSAY Selzentry as an HIV Trofile Dependent Drug HIV Drug Resistance Tests HIV STATISTICS AND HEALTHCARE COST AS A FACTOR FOR COMPANION DIAGNOSTICS SALES FORECAST TABLE 50 HIV STATISTICS AND HEALTHCARE COST IN THE U.S., HIV DRUG MARKET TABLE 51 MARKET FOR HIV DRUGS WORLDWIDE 2010 AND 2015 ($ BILLIONS) CURRENT PARTNERSHIPS AND COLLABORATIONS FOR COMPANION DIAGNOSTICS FOR INFECTIOUS DISEASES TABLE 52 RECENT PARTNERSHIPS IN THE FIELD OF COMPANION DIAGNOSTICS FOR INFECTIOUS DISEASES BETWEEN DIAGNOSTICS AND PHARMACEUTICAL COMPANIES MitoSciences/University of Oregon LabCorp (Monogram Bioscience)/Pfizer /Shering Plough/Progenics/Gilead Science/Avexa Lab21/Innogenetics CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS IN OTHER DISEASES TABLE 53 CURRENT COMPANION DIAGNOSTICS PRODUCTS IN DIFFERENT CLINICAL APPLICATIONS ALLOMAP GENE PROFILE HLA TESTING COMPANION DIAGNOSTICS TESTS DEVELOPMENT IN DRUG METABOLISM Cytochrome P450 2C9 (CYP2C9) NAT (N acetyltransferase) Amplichip CYP2D6/CYP2C SEROLOGY 7 TEST FOR IBD Serology 7 Test for IBD (Continued) CHAPTER FIVE: MARKET SUMMARY TABLE 54 LIST OF COMPANION DIAGNOSTICS PRODUCTS ON THE MARKET MENTIONED IN THE REPORT TABLE 54 (CONTINUED)
13 TABLE 55 PRODUCTS IN EACH INDUSTRY SECTOR IN THE COMPANION DIAGNOSTICS INDUSTRY (%) FIGURE 8 PRODUCTS IN EACH INDUSTRY SECTOR IN THE COMPANION DIAGNOSTICS INDUSTRY (%) TABLE 56 U.S. NET SALES OF ONCOTYPE AND TROFILE, THROUGH 2015 ($ MILLIONS) FIGURE 9 U.S. NET SALES OF ONCOTYPE AND TROFILE ($ MILLIONS) TABLE 57 ESTIMATE FOR COMPANION DIAGNOSTICS TEST MARKET FOR THERAPY SELECTION, THROUGH 2015 ($ MILLIONS) FIGURE 10 ESTIMATE FOR COMPANION DIAGNOSTICS TEST MARKET FOR THERAPY SELECTION 2010 AND 2015 ($ MILLIONS) CHAPTER SIX SELECTED COMPANIES OVERVIEW ABBOTT LABORATORIES BIOMERIEUX SA CELERA CORP CLINICAL DATA INC DAKO A/S LABCORP QIAGEN MANCHESTER LTD. (FORMER DXS LTD) QUEST DIAGNOSTICS INC ROCHE DIAGNOSTICS (DIVISION OF ROCHE GROUP) CHAPTER SEVEN: DIRECTORY OF COMPANIES DIRECTORY OF COMPANIES DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED)
Personalized medecine Biomarker
Patient Disease Diagnosis Risk prediction Personalized medecine Biomarker Targeted therapies Diagnostic Theranostic: Efficay Toxicity Treatment 1 THE CASE FOR PERSONALIZED MEDICINE IS COMPELLING.. Toxicity
More informationGASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,
More informationCHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST
More informationCompanion Diagnostics: Technologies and Markets. Robert Hunter. March Report Code: BIO077C
Companion Diagnostics: Technologies and Markets March 2017 Robert Hunter Report Code: BIO077C Table of Contents Chapter 1: Introduction... 1 Study Goals and Objectives... 1 Reasons for Doing the Study...
More informationPrevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March 2017 Usha Nagavarapu Report # PHM113B Table of Contents Chapter 1 Introduction... 1 Introduction... 1 Study goals and
More informationISPOR 4 th Asia Pacific Conference IP2 Gilberto de Lima Lopes
Health Economic Considerations for Personalized Medicine in Asia: Using Genomic Profiling to Guide Treatment Decisions in Early Breast Cancer Gilberto de Lima Lopes, Jr., M.D., M.B.A Assistant Director
More informationADULT ENTERAL NUTRITION PARENTERAL NUTRITION U.S. REGULATORY ENVIRONMENT THE INFANT FORMULA ACT OF The 1986 Amendments
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE AND FORMAT... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS...
More informationLIQUID BIOPSY RESEARCH TOOLS, SERVICES AND DIAGNOSTICS: GLOBAL MARKETS
LIQUID BIOPSY RESEARCH TOOLS, SERVICES AND DIAGNOSTICS: GLOBAL MARKETS BIO150A January 2016 John Bergin Project Analyst ISBN: 1-62296-224-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
More informationSegment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage
Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (35 years): Forecast to 2022 By Type - Pap Test, HPV Test,
More informationDNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS
DNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS BIO067B July 2014 Jon Evans Project Analyst ISBN: 1-56965-883-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationGlobal Skin Cancer Diagnosis and Therapeutics Market Research and Forecast
Report Information More information from: https://www.wiseguyreports.com/reports/3186925-global-skin-cancer-diagnosis-and-therapeuticsmarket-research Global Skin Cancer Diagnosis and Therapeutics Market
More informationU.S. AND GLOBAL MARKETS FOR ETHICAL NUTRITION IN HEALTHCARE
U.S. AND GLOBAL MARKETS FOR ETHICAL NUTRITION IN HEALTHCARE FOD029E January 2015 Mary Anne Crandall Project Analyst ISBN: 1-62296-005-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationGLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
More informationRENAL BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
RENAL BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS BIO138A January 2015 Cheng-Yuk Lee Project Analyst ISBN: 1-62296-003-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 024 USA 866-285-7215 (toll-free
More informationCustom Intelligence. Alzheimer s Disease Landscape Summary
Custom Intelligence Alzheimer s Disease Landscape Summary Prepared August 21 Alzheimer s Disease Landscape: Executive Summary Current standard of care in Alzheimer s Disease (AD) consists of symptomatic
More informationGLOBAL GENETIC TESTING MARKET. Growth Trends & Forecasts. mordorintelligence.com
GLOBAL GENETIC TESTING MARKET 2014-2020 Growth Trends & Forecasts mordorintelligence.com TABLE OF CONTENTS 1 Introduction 1.1 Report Description 1.2 Research Methodology 2. Genetic Testing Market Overview
More information9/23/2014. Wisconsin Association of Physician Assistants October 10, 2014
Personalized (Precision) Medicine Wisconsin Association of Physician Assistants October 10, 2014 Disclosures I am an employed by Promega Corporation, a Madison based international biotechnology company
More informationOncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
More information1.5. Research Areas Treatment Selection
1.5. Research Areas Cancer biomarker research embraces many areas of study, including tumorigenesis, metastasis, clinical trial and surrogate endpoints, cell isolation, target identification, drug resistance,
More informationGLOBAL & USA CANCER BIOMARKER MARKET to 2018
GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline
More informationCHAPTER FOUR: MARKET SIZE AND GROWTH SLEEP MEDICATIONS MARKET PRESCRIPTION... 40
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR STUDY... 1 SCOPE OF STUDY... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS... 2 BCC
More informationRoche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationPancreatic Cancer Market Research Report- Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/1638 Pancreatic Cancer Market Research Report- Global Forecast till 2023 Report / Search Code: MRFR/HC/1107-HCRR Publish
More informationBRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
More informationOrgan Transplantation Market Research Report- Global Forecast Till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/915 Organ Transplantation Market Research Report- Global Forecast Till 2023 Report / Search Code: MRFR/HC/0410-HCRR
More informationBank of America 38 th Annual Investment Conference. San Francisco, CA September 17 th, 2008
Bank of America 38 th Annual Investment Conference 1 San Francisco, CA September 17 th, 2008 Introduction This slide presentation contains forward-looking statements which are subject to change based on
More informationTABLE OF CONTENTS. HLC102A - Continuous Glucose Monitoring (CGM): Technologies and Global Markets
TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 1 STUDY GOALS AND OBJECTIVES 1 REASONS FOR DOING THIS STUDY 1 CONTRIBUTIONS TO THE STUDY AND INTENDED AUDIENCE 1 SCOPE AND FORMAT 1 METHODOLOGY AND INFORMATION
More informationCirculating Tumor Cells (CTC) Technologies
Table of Contents MIR036 I. SCOPE AND METHODOLOGY Scope of the Study Analytics and data presented in this report pertain to several parameters such as - Research Methodology This report is uniquely researched
More informationOpportunities and Challenges in the Development of Companion Diagnostics
Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine
More informationOncology Therapeutics Market in India to 2018
Oncology Therapeutics Market in India to 2018 Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players GBI Research Report Guidance GBI Research
More informationINCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS
INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationHealth Systems Adoption of Personalized Medicine: Promise and Obstacles. Scott Ramsey Fred Hutchinson Cancer Research Center Seattle, WA
Health Systems Adoption of Personalized Medicine: Promise and Obstacles Scott Ramsey Fred Hutchinson Cancer Research Center Seattle, WA Cancer Pharmaceutical Pricing Bach P. NEJM 2009;360:626 Opportunities
More informationTHYROID HORMONE THERAPY TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ANALYST S CREDENTIALS...
More informationFitting the Treatment to the Patient Roche Personalized Healthcare. February 24, 2012
Fitting the Treatment to the Patient Roche Personalized Healthcare February 24, 2012 Roche Group Pharmaceuticals Roche Pharma Genentech Chugai Applied Science Molecular Professional Tissue Diabetes Care
More informationChronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is
More informationMARCH 2017 RESEARCH REPORT
1 MARCH 2017 RESEARCH REPORT LIQUID BIOPSY MARKETS by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides Liquid Biopsy
More informationJAK AND PI3K SIGNALING PATHWAY MARKETS
JAK AND PI3K SIGNALING PATHWAY MARKETS PHM168A April 2014 Shalini Shahani Dewan Project Analyst ISBN: 1-56965-793-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationJ.P. Morgan. 27 th Annual Healthcare Conference. San Francisco January 14 th, 2009
J.P. Morgan 27 th Annual Healthcare Conference 1 San Francisco January 14 th, 2009 Introduction This slide presentation contains forward-looking statements which are subject to change based on various
More informationCancer Immunotherapy Artificial Intelligence: Market Shares, Strategies, and Forecasts, 2017 to 2023
Cancer Immunotherapy Artificial Intelligence: Market Shares, Strategies, and Forecasts, 2017 to 2023 Table of Contents Cancer Immunotherapy Artificial Intelligence: Executive Summary The study is designed
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationVaccine Technologies and Global Markets
A BCC Research Pharmaceutical Report and Global Markets PHM014D Use this report to: Learn about the strengths and weaknesses of each category of human and veterinary vaccine to prevent or treat infectious
More informationIn Situ Hybridization: Market Strategies and Forecasts, US,
In Situ Hybridization: Market Strategies and Forecasts, US, 2018-2024 Table of Contents In Situ Hybridization: Executive Summary The study is designed to give a comprehensive overview of the In Situ Hybridization
More informationBlood Glucose Test Strip Market Research Report- Global Forecast till 2020
Report Information More information from: https://www.marketresearchfuture.com/reports/976 Blood Glucose Test Strip Market Research Report- Global Forecast till 2020 Report / Search Code: MRFR/MED/0470-CRR
More informationSickle-cell Anemia Therapeutics Market in the US
Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sector Publishing Intelligence Limited (SPi) has been marketing business and market
More informationREGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
More informationANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS
ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationTHERAPIES AND BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE
THERAPIES AND BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE PHM125A January 2013 Willem Westra Project Analyst ISBN: 0-89336-715-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215,
More informationSystems Thinking in Personalized Medicine
Systems Thinking in Personalized Medicine Devon C. Campbell Head, Engineering and Systems Novartis Molecular Diagnostics MIT SDM Systems Thinking Conference October 25, 2011 Agenda Personalized medicine
More informationSleep apnea devices Market Research Report- Global Forecast To 2022
Report Information More information from: https://www.marketresearchfuture.com/reports/2061 Sleep apnea devices Market Research Report- Global Forecast To 2022 Report / Search Code: MRFR/HC/1529-HCRR Publish
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationINTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS
INTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS HLC046C November 2014 Mary C. Patton Project Analyst ISBN: 1-56965-982-6 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationGlobal Magnetic Resonance Imaging (MRI) Systems Market Research Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Magnetic Resonance Imaging (MRI) Systems Market Research Report 2016 Global Magnetic Resonance Imaging (MRI)
More informationEconomic Aspects of Personalised Health Care
Economic Aspects of Personalised Health Care Thomas D. Szucs European Center of Pharmaceutical Medicine, University of Basel Disclaimer The explanations, opinions and facts expressed relate to the personal
More informationCognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015 Cognitive Impairment Associated
More informationOncology Market Opportunities, Strategies, and Forecasts, 2006 to Oncology. Picture by Susie Eustis MOUNTAINS OF OPPORTUNITY
Oncology Market Opportunities, Strategies, and Forecasts, 2006 to 2012 Oncology Picture by Susie Eustis MOUNTAINS OF OPPORTUNITY WinterGreen Research, Inc. Lexington, Massachusetts www.wintergreenresearch.com
More informationOncology Market Forecast To 2013
Oncology Market Forecast To 2013 How do you uncover the threats and opportunities that your oncology drug will face this year, next year and each year after that? Our new report answers your questions
More informationNUTRACEUTICALS: GLOBAL MARKETS
NUTRACEUTICALS: GLOBAL MARKETS FOD013E November 2014 Natraj Pandal Project Analyst ISBN: 1-56965-992-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within the
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationGLOBAL NEUROSTIMULATION MARKET
GLOBAL NEUROSTIMULATION MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d
More informationPHM029D - Antifungal Drugs: Technologies and Global Markets TABLE OF CONTENTS
TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 1 STUDY GOALS AND OBJECTIVES 1 REASONS FOR DOING THIS STUDY 1 INTENDED AUDIENCE 2 SCOPE OF REPORT 2 METHODOLOGY 2 INFORMATION SOURCES 2 ANALYST CREDENTIALS 3 RELATED
More informationPrecision Medicine. Wendy Chung, MD PhD Director of Clinical Genetics Columbia University
Precision Medicine Wendy Chung, MD PhD Director of Clinical Genetics Columbia University What is precision medicine? Providing the right treatment for the right patient at the right time and engaging the
More informationDIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC)
DIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC) R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p
More informationPersonalised Healthcare. will it deliver? Bob Holland Head of Personalised Healthcare & Biomarkers Innovative Medicines AstraZeneca R&D
Personalised Healthcare x will it deliver? Bob Holland Head of Personalised Healthcare & Biomarkers Innovative Medicines AstraZeneca R&D Personalised Healthcare It is delivering! Bob Holland Head of Personalised
More informationORGANIC FOODS AND BEVERAGES: GLOBAL MARKETS
ORGANIC FOODS AND BEVERAGES: GLOBAL MARKETS FOD067A June 2014 Natraj Pandal Project Analyst ISBN: 1-56965-851-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationTABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationCANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS
CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS PHM173A January 2015 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-008-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationPatients Driving Progress
Patients Driving Progress Ellen V Sigal, PhD WIN Symposium 2018 June 25, 2018 Paris, France Nothing to disclose The Evolution of Patient Advocacy The Agnew Clinic, Thomas Eakins (1899) Partial mastectomy
More informationExecutive Summary. Reproduction prohibited v
Kinases are a large family of proteins that have now become firmly established as a major class of drug targets for the pharmaceutical industry. The sequencing of the Human Genome has led to the identification
More informationGRNVAC DCVax-Brain AGS Glionix CYT004-MelQbG CDX-110 (PF ) GI TABLE 23 OCCURRENCE OF
CHAPTER ONE: INTRODUCTION.1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY... 2 INFORMATION SOURCES... 3 AUTHOR S CREDENTIALS...
More informationREFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical
More informationBOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS
BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS BIO022G August 2015 Kim Lawson Project Analyst ISBN: 1-62296-134-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationSynribo (Chronic Myeloid Leukemia)
Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 GDHC1141DFR / Published May 2013 Executive Summary Synribo (omacetaxine mepesuccinate): Key Metrics in CML Markets 2012 Synribo Sales
More informationRoche at a Glance An Introduction to our Company. February 2013
Roche at a Glance An Introduction to our Company February 2013 Basic facts at a glance Founded 1896 in Basel, Switzerland Founding families still hold majority stake Employing 80,000 people Currently active
More informationCytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019
Reference Code: GDHC504PRT Publication Date: January 2013 Cytomegalovirus Infections: Key Metrics in Seven Major Pharmaceutical Markets 2012 Epidemiology* Prevalent population (CMV prevalent cases in general
More informationPharma 2020: Which Path will you take? Automation in Pharma Congress, Leiden 8 October 2009 Loic Kubitza & Arwin van der Linden
Pharma 2020: Which Path will you take? Automation in Pharma Congress, Leiden 8 October 2009 Loic Kubitza & Arwin van der Linden Agenda Trends and implications Potential business models Personalized medicine
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationSAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB
Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationLonasen (Blonanserin) Lullan (Perospirone) Saphris/Sycrest (Asenapine, ORG 5222, SCH ) Saphris/Sycrest (Continued)...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 2 INTENDED AUDIENCE... 2 SCOPE OF REPORT... 3 METHODOLOGY... 3 INFORMATION SOURCES... 4 AUTHOR S CREDENTIALS...
More informationREFERENCE CODE GDHC398DFR PUBLICAT ION DATE M ARCH 2014 SAFINAMIDE (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC398DFR PUBLICAT ION DATE M ARCH 2014 SAFINAMIDE (PARKINSON S DISEASE) - Executive Summary The table below summarizes the key metrics for Safinamide in the 8MM Parkinson s disease (PD)
More informationCIRCULATING TUMOR CELL (CTC) DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS
CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS PHM153A January 2014 Usha Nagavarapu Project Analyst ISBN: 1-56965-671-1 BCC Research 49 Walnut Park, Building 2 Wellesley, MA
More informationREFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) GILOTRIF (NON-SMALL CELL LUNG CANCER) - Executive Summary Gilotrif: Key Metrics in NSCLC Markets 2022 Gilotrif
More informationCHAPTER THREE: INDUSTRY OVERVIEW... 6 HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY... 6 HISTORICAL PERSPECTIVE OF THE (CONTINUED)...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR STUDY... 1 SCOPE OF STUDY... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS... 2 DISCLAIMER...
More informationSAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report
More informationBuilding a Premier Oncology Biotech
Corporate Presentation Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO February 2019 Forward-Looking Statements All of the statements in this presentation that are not statements
More informationCorporate Presentation. August 2016
v Corporate Presentation August 2016 Safe harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
More informationOperatory Units TABLE 20 SELECT MANUFACTURERS AND DISTRIBUTORS OF DENTAL FURNITURE TABLE 20 (CONTINUED) Cavity Preparation Systems
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE AND FORMAT... 1 METHODOLOGY... 1 RELATED BCC STUDIES... 2 ANALYST CREDENTIALS... 2 BCC ON-LINE SERVICES...
More informationDelivering Value Through Personalized Medicine: An Industry Perspective
Delivering Value Through Personalized Medicine: An Industry Perspective Josephine A. Sollano, Dr.PH Head, Global HEOR and Medical Communications Pfizer Oncology, NY, USA josephine.sollano@pfizer.com What
More informationREFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Stivarga for colorectal cancer (CRC) in the eight major
More informationUsing the Mozambique National Quality Policy to Encourage Biomedical Research, Innovation, & Infrastructure Investment
Using the Mozambique National Quality Policy to Encourage Biomedical Research, Innovation, & Infrastructure Investment Rachael Eckles, JD/MA Director, Regulatory Policy Bristol-Myers Squibb August 10,
More informationMelanoma Research Alliance-Pfizer Academic-Industry Partnership Awards
Melanoma Research Alliance-Pfizer Academic-Industry Partnership Awards Wendy K.D. Selig, President & CEO, MRA Julia Perkins, M.D. Medical Director, Oncology, Pfizer Melanoma Research Alliance Mission:
More informationMyriad Genetics Corporate Presentation 6/4/13
Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationInfluenza Vaccination Market Research Report Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/1621 Influenza Vaccination Market Research Report Global Forecast till 2023 Report / Search Code: MRFR/HC/1090-HCRR
More informationBIOPSY DEVICES: TECHNOLOGY AND GLOBAL MARKETS
BIOPSY DEVICES: TECHNOLOGY AND GLOBAL MARKETS HLC171B March 2016 Yojana Jeevane Project Analyst ISBN: 1-62296-257-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationGlobal Standard Radiography Film X-Ray Film Printer Market Research Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Standard Radiography Film X-Ray Film Printer Market Research Report 2016 Global Standard Radiography Film
More informationPatient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017
Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of
More information